Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026
Rhea-AI Summary
Aytu BioPharma (Nasdaq: AYTU) will participate in a Fireside Q&A at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026, at 10:30 a.m. Pacific time at the Bellagio Resort & Hotel.
Management will also host in-person 1x1 investor meetings June 17–18, 2026.
Positive
- None.
Negative
- None.
News Market Reaction – AYTU
In the Jun 2 session, AYTU declined 2.33%, reflecting a moderate negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 18 | Investor conference | Neutral | -0.9% | Announcement of participation in Lytham Partners Spring 2026 investor conference. |
| May 13 | Earnings report | Negative | +0.9% | Fiscal 2026 Q3 results showing revenue decline and a net loss of $5.6M. |
| May 06 | Earnings date | Neutral | -3.5% | Scheduling of fiscal 2026 Q3 earnings release and conference call details. |
| Feb 03 | Earnings report | Negative | -10.3% | Fiscal 2026 Q2 results with lower revenue and a $10.6M net loss. |
| Jan 27 | Earnings date | Neutral | +0.8% | Announcement of Q2 fiscal 2026 earnings release timing and access details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings reports have produced the strongest moves, with one notable selloff on weaker results and a divergence where shares rose despite soft Q3 metrics. Investor-day and conference communications have had relatively modest price impact.
Over the last six months, AYTU’s key catalysts have been earnings and investor outreach. Fiscal 2026 Q2 and Q3 results highlighted falling revenue and net losses as the company pivots to CNS medicines and launches EXXUA, with notable moves of -10.31% and a modest 0.89% gain. Earnings-date announcements around Feb 3 and May 13 saw smaller reactions. Prior conference participation on May 28, 2026 also generated limited volatility, similar in nature to the current Planet MicroCap appearance.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DENVER, CO / ACCESS Newswire / June 1, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced that it will be participating in a Fireside Q&A hosted by Lake Street Capital Markets at the Planet MicroCap Las Vegas 2026 Investor Conference Powered by MicroCapClub on Wednesday, June 17, 2026, at 10:30 a.m. Pacific time at the Bellagio Resort & Hotel.
To access the live webcast, please use the following information:
Planet MicroCap Las Vegas 2026 Investor Conference Powered by MicroCapClub
Date: Wednesday, June 17, 2026
Time: 10:30 a.m. Pacific time
Webcast: https://event.summitcast.com/view/bpjo3VVjZ25pp6SXpUua92/j8zQrjvPykncFs66WaA7AS
Management also will be conducting investor meetings at the conference on June 17-18. If you would like to schedule a 1x1 investor meeting with Aytu, and to attend the Planet MicroCap Las Vegas 2026 investor conference, please make sure you are registered here: REGISTER. Meetings will be scheduled and conducted in person at the conference venue: Bellagio Resort & Hotel in Las Vegas, NV. The Planet MicroCap Las Vegas 2026 investor conference website is available here: HOME PAGE.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to delivering the Company's medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visit aytubio.com or follow us on LinkedIn.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
rselhorn@aytubio.com
Robert Blum
Lytham Partners
aytu@lythampartners.com
SOURCE: Aytu BioPharma, Inc.
View the original press release on ACCESS Newswire